Surface Oncology, Inc. (SURF) financial statements (2020 and earlier)

Company profile

Business Address 50 HAMPSHIRE STREET, 8TH FLOOR
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments105159
Cash and cash equivalents4783
Short-term investments5876
Receivables00
Prepaid expense25
Other undisclosed current assets 1
Total current assets:108165
Noncurrent Assets
Operating lease, right-of-use asset15
Property, plant and equipment78
Restricted cash and investments21
Other noncurrent assets00
Total noncurrent assets:249
TOTAL ASSETS:132174
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77
Accounts payable33
Accrued liabilities01
Employee-related liabilities33
Deferred revenue5
Debt3 
Deferred rent credit 0
Contract with customer, liability15
Other liabilities11
Other undisclosed current liabilities35
Total current liabilities:1927
Noncurrent Liabilities
Long-term debt and lease obligation22 
Long-term debt, excluding current maturities5 
Operating lease, liability17
Liabilities, other than long-term debt3444
Deferred revenue34
Contract with customer, liability39
Deferred rent credit 5
Total noncurrent liabilities:5644
Total liabilities:7571
Stockholders' equity
Stockholders' equity attributable to parent57103
Common stock00
Additional paid in capital178170
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(122)(67)
Total stockholders' equity:57103
TOTAL LIABILITIES AND EQUITY:132174

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:1559
Operating expenses(73)(69)
Operating loss:(57)(9)
Nonoperating income
(Investment Income, Nonoperating)
10
Other undisclosed income from continuing operations before equity method investments, income taxes2 
Loss before gain (loss) on sale of properties:(55)(9)
Other undisclosed net income 2
Net loss attributable to parent:(55)(7)
Preferred stock dividends and other adjustments (0)
Net loss available to common stockholders, diluted:(55)(7)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(55)(7)
Comprehensive loss:(55)(7)
Other undisclosed comprehensive income, net of tax, attributable to parent00
Comprehensive loss, net of tax, attributable to parent:(55)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: